Montclair, NJ, and Oxford, MS ― January 5, 2010 ― Jack Mycka, Global President and CEO, and Mick Kolassa, Chairman of MME, LLC, respectively, and Renato Dellamano, President of MME Europe and ValueVector, Milan, Italy, have published two articles on good research practices for measuring drug costs in cost-effectiveness analyses in the January/February issue of Value in Health (Vol. 13, No.1, 2010). These articles are part of ISPOR’s Drug Cost Task Force Report. Mycka, Kolassa, and Dellamano were chosen to serve on the Task Force because of their experience in using drug cost information while working in industry and academia.
For preliminary copies of the articles and more information on the task force, please visit the ISPOR Web site.
For the final versions of the articles and the entire table of contents for this issue of Value in Health, see the Wiley InterScience site.
For additional information about Medical Marketing Economics, please contact us at 662.281.0502 or via e-mail at info@m2econ.com.
